TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04344054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB
Description: 1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB
Description: 1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8
Description: 0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8
Description: 0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8
Description: 0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8
Description: 0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB birth dose
Description: 1.0 mL of the thawed rotavirus vaccine to be administered orally at birth.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8 Booster dose
Description: 0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8 Booster dose
Description: 0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age
Study: NCT06467500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104)
Description: Subjects participated in a study where they received cadonilimab intravenously at 6mg/kg every two weeks, prepared in 100mL of normal saline (0.9% NaCl), with a final concentration range of 0.2-5.0mg/mL. The infusion solution must be used within 4 hours of preparation. Treatment continued until disease progression (PD), unacceptable toxicity, or 24 months, whichever came first. Patients who investigators deemed could still benefit from cadonilimab post-PD were allowed continued treatment. Chemotherapy regimens were selected by investigators based on prior medication use, including gemcitabine, pemetrexed, docetaxel, albumin-bound paclitaxel, or vinorelbine as second- or third-line therapy
Study: NCT05481580

Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontal probing
Description: The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment

Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontal probing
Description: The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment
Study: NCT06232863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH009
Description: Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
Study: NCT04335110

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)
Description: STELLA consists of 8 sessions: 4 sessions one-to-one, with the Care Partner and a Guide, and then 4 sessions with one Guide with up to four Care Partners (total small group will include as few as two and as many as 4 Care Partners) Each weekly session takes about 1 hour. The first four sessions allow for development of the Care Partner-Guide working relationship. In these sessions, the Care Partners identify behaviors (both the person with dementia's and the Care Partner's) which are upsetting to the family. Care Partners will be taught to use an Activator, Behavior, Consequence (ABC) approach to identify activators of behaviors, the behaviors, and consequences of the behaviors. After they identify the ABCs, they will develop a plan to address the behavior and then test it. After the four one-to-one sessions, Care Partners will meet in small groups with a Guide. Effective communication strategies, engagement in pleasant events, and coping will be addressed.
Study: NCT05516212

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CAFMONO supplementation
Description: CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CAFMIPS_1 supplementation
Description: CAFMIPS_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CAFMIPS_2 supplementation
Description: CAFMIPS_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
Study: NCT05880563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-RoSMA-18-d6
Description: \[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-RoSMA-18-d6
Description: \[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
Study: NCT05491174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-Informed skills group
Description: 10 session group ran weekly by junior staff (P-BIFs) following a standardised manual-based protocol which can be delivered either face-to-face or via video-call. The groups will be skills-based, covering each of the four modules of DBT: Mindfulness, Distress Tolerance, Emotion Regulation and Interpersonal Effectiveness.
Study: NCT06175702

Intervention type: DRUG
Intervention: Vincristine
Description: dose 1.5 mg/m2 at days 1, 8, 15 and 22

Intervention type: DRUG
Intervention: Vincristine
Description: dose 1.5 mg/m2 at days 1, 8, 15 and 22

Intervention type: DRUG
Intervention: Dexamethasone
Description: 40 mg on days 1-2, 8-9,15-16 and 22-23

Intervention type: DRUG
Intervention: Dexamethasone
Description: 40 mg on days 1-2, 8-9,15-16 and 22-23

Intervention type: DRUG
Intervention: Imatinib
Description: 600 mg per day from 1 to up to 5 years

Intervention type: DRUG
Intervention: Imatinib
Description: 600 mg per day from 1 to up to 5 years

Intervention type: DRUG
Intervention: Cytarabine
Description: 1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion

Intervention type: DRUG
Intervention: Cytarabine
Description: 1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion

Intervention type: DRUG
Intervention: Mercaptopurine
Description: 50 mg/m2 on days 1 to 28 of maintenance

Intervention type: DRUG
Intervention: Mercaptopurine
Description: 50 mg/m2 on days 1 to 28 of maintenance

Intervention type: DRUG
Intervention: Methotrexate
Description: 1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance

Intervention type: DRUG
Intervention: Methotrexate
Description: 1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance

Intervention type: DRUG
Intervention: Ponatinib
Description: 15 mg per day from consolidation start up to 5 years

Intervention type: PROCEDURE
Intervention: allogeneic stem cell transplantation
Description: Allogeneic stem cell transplantation from hematpoietic stem cells progenitors of familiar or not familiar origin. Cord blood transplantation can also be done.

Intervention type: PROCEDURE
Intervention: Total body irradiation
Description: Fractionated dose with total dose of 12 Gy between days -4 and -1 of allogeneic stem cell transplantation (alloSCT)

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: 60 mg/kg on days -6 and -5 before alloSCT

Intervention type: DRUG
Intervention: Fludarabine
Description: 30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
Study: NCT05974020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention will be applied to the control group, and information will be given on general foot care instructions and the use of appropriate shoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrinsic Muscle Training
Description: In addition to general foot care instructions and briefings on the use of appropriate shoes, intrinsic muscle training including alternating toe movement, toes picking up sheets, opening and closing the toes, pinching the toe separators, toe transitions and short foot exercises will be implemented.~Additionaly, warm-up exercises, ankle exercises and functional exercises will be included in the program.
Study: NCT04981665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be performed after curative resection (4±1w)
Study: NCT05974020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: In addition to general foot care instructions and information on the use of appropriate shoes, warm-up exercises, ankle exercises, functional exercises and intrinsic muscle training, the participants will be given a walking program for aerobic exercise.
Study: NCT04878874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape
Description: Kinesiology Tape is applied without creating any tension over low back
Study: NCT05913388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Administered orally twice daily at 400mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered at a fixed dose of 200 mg every 3 weeks intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Administered at a fixed dose of 200 mg every 3 weeks intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally twice daily at 400mg.
Study: NCT06141382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: English Langugae-Sensory based narrative intervention
Description: Sensory based narrative intervention (auditory, visual and tactile stimulations) in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: English Language-Narrative intervention
Description: Narrative intervention with the help of only pictures in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administred thrice a week in 45-minute long session for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urdu Langusge-Sensory based narrative intervention
Description: Sensory based narrative intervention (auditory, visual and tactile stimulations) in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urdu Language-Narrative intervention
Description: Narrative intervention with the help of only pictures in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilingual-Sensory based narrative intervention
Description: Sensory based narrative intervention (auditory, visual and tactile stimulations) in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilingual-Narrative intervention
Description: Narrative intervention with the help of only pictures in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
Study: NCT05900609

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WholeFiber
Description: WholeFiberTM is a product with high levels of prebiotic dietary fibers (\~85%) mainly consisting of inulin, and some pectin, hemi-cellulose and cellulose that is derived from the root vegetable, chicory roots.~Fiber guidelines:~Subjects receive a booklet with recipes high in fiber. Subjects are recommended to use 2 recipes per day + a snack. Estimated average intake via the recipes in the recipe booklet is 24 grams/day.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kombucha
Description: The kombucha is produced by a minimum three-month long fermentation process. It is a live fermented herbal drink essence, without refined sugar, and an unpasteurized, organic product.~Fermented food guidelines:~Study participants in the fermented foods arm are asked to use 3 additional servings of fermented food per day, using the fermented food list / recipe booklet.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin DE19/21
Description: Maltodextrin DE19/21 is a digestible carbohydrate, that is completely digested and does not reach the colon, which makes it a suitable placebo dietary compound and the reason why it is frequently used in comparable studies.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation).
Study: NCT04873349

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)
Description: two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)
Description: two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group
Study: NCT04805281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.
Description: wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Dislicate IPS e.max crown
Description: wear of lithium disilicate IPS e.max crown in posterior teeth
Study: NCT05493033

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomotic after LRC
Description: Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomotic after LRC
Description: The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
Study: NCT05829902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal extract drink
Description: 30 ml drink containing 600 mg of lemon balm extract, tea leaves, brown sugar and flavoring agent, two weeks daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 ml placebo drink containing maltodextrin, tea leaves, brown sugar and flavoring agent, two weeks daily
Study: NCT05619744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7616789
Description: RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7616789
Description: RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7616789
Description: RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Study: NCT05267041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: One questionnaire between diagnostic annoucement and first line treatement

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: One questionnaire 6 months later after first line treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: One questionnaire before second line treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: One questionnaire 6 months later after second line treatment
Study: NCT05054361

Intervention type: DIAGNOSTIC_TEST
Intervention: Lactulose/Mannitol Test
Description: After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lactulose/Mannitol Test
Description: After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
Study: NCT06155669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
Study: NCT06527430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg bupivacaine
Description: Spinal anesthesia was applied to the patients with 4 mg bupivacaine in the lateral decubitus position.
Study: NCT05054361

Intervention type: DIAGNOSTIC_TEST
Intervention: Lactulose/Mannitol Test
Description: After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
Study: NCT06527430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 mg bupivacaine
Description: Spinal anesthesia was applied to the patients with 6 mg bupivacaine in the lateral decubitus position.
Study: NCT05726526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIEWER virtual care platform
Description: VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
Study: NCT05062239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative
Description: Discontinuance of prior statin therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No-intervention.
Description: Continuance of prior statin therapy